ArticleFrontiers in pharmacology2025
Exploring the role of epigenetic regulation in cancer prognosis with epigenetic score.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification and Prognostic Analysis of Immune-Related Genes Co-Regulated by Key Histone Modifications in Breast Cancer.Current issues in molecular biology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The mechanisms of epigenetic regulation emerge as a fundamental determinant in the complex landscape of cancer initiation and advancement. However, the specific impact of epigenetic regulation on cancer progression remains unclear. To explore the relationship between epigenetic regulation and cancer progression, we utilized transcriptomic data from The Cancer Genome Atlas (TCGA) datasets to investigate the association. Methods: We obtained transcriptomic data of epigenetic gene dataset from the TCGA database and calculated an epigenetic score using the Least Absolute Shrinkage and Selection Operator (LASSO) Cox model. Additionally, we created a nomogram that integrates the epigenetic score and clinical features, providing a more comprehensive tool for tumor patients prognosis assessment. Results: We calculated the epigenetic score based on the expression levels of epigenetic-related genes. The nomogram we developed incorporates the epigenetic score and clinical characteristics. The epigenetic score was positively correlated with the expression of genes related to hallmarkers of cancer, including glycolysis, epithelial-mesenchymal transition (EMT), cell cycle, DNA repair, angiogenesis, and inflammatory response. Furthermore, we performed gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) analysis to explore the signaling pathways and biological processes in high epigenetic score group. Conclusion: The epigenetic scoring system developed in this investigation represents an innovative approach that demonstrates remarkable potential in forecasting survival trajectories across diverse cancer types. These groundbreaking insights not only illuminate the intricate interactions between epigenetic mechanisms and gene expression regulation in oncological contexts, but also indicate that the derived epigenetic metric could potentially emerge as a significant prognostic biomarker for cancer outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.